Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Roche Molecular Systems, INC.

Approvalsdevice change approved (PMA)4 Nov 2026

Roche Molecular Systems, INC.

4 Nov 2026: Device change approved (PMA) · Roche cobas® KRAS Mutation Test. Recorded in the openFDA device PMA data.

View the source record

Decided
4 Nov 2026
Device
Roche cobas® KRAS Mutation Test
Specialty
Pathology
Type
Supplement (Special (Immediate Track))
Reason
Labeling Change - Indications/instructions/shelf life/tradename
Reference
P140023 S034
Location
Pleasanton, CA
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Roche Molecular Systems, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Roche Molecular Systems, INC. in our registers.

More in Pathology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.